Srikanth Neelakantham

Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals

Tania Garito, Ronenn Roubenoff, Marcus Hompesch et al. · Diabetes Obesity and Metabolism · 2017 · 86 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers

Michael K. Badman, Jin Chen, Sachin N. Desai et al. · Clinical Pharmacology in Drug Development · 2019 · 71 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

Yan He, Georgios Foteinos, Srikanth Neelakantham et al. · Diabetes Obesity and Metabolism · 2013 · 34 citations

Medicine, Endocrinology, Pharmacology +17

Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study

Christoph Schramm, Gideon M. Hirschfield, Andrew L. Mason et al. · Journal of Hepatology · 2018 · 28 citations

Medicine, Pharmacology, Pharmacotherapy +11

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers

Veit J. Erpenbeck, Eva Vets, Lien Gheyle et al. · Clinical Pharmacology in Drug Development · 2015 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10